Interní Med. 2008; 10(3): 126-128

Use of beta-blockers in patients with diabetes mellitus

prof. MUDr. Jiří Vítovec CSc, prof. MUDr. Jindřich Špinar CSc., FESC
I. interní kardioangiologická klinika FN u sv. Anny v Brně

The article presents a review of beta-blocker use (BB) in patients with heart disease who suffer also from diabetes mellitus (DM). With regard to possible metabolic consequences of treatment with beta blockers and concealing of some of warning signals of hypoglycaemia we always should consider indication of beta blockers, that may have in many patients with cardiovascular disease significant influence on mortality decrease. Physicians must always in these cases evaluate benefit of the treatment in comparison to its risk.

Keywords: beta-blockers, hypertension, heart failure, coronary heart disease, arrhythmia, diabetes mellitus

Published: May 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J, Špinar J. Use of beta-blockers in patients with diabetes mellitus. Interní Med. 2008;10(3):126-128.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Antonová P. Betablokátory, Remedia 2003; 13: 125-130. Go to original source...
    2. Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227-2236. Go to original source... Go to PubMed...
    3. Bultas J. Mizí další kontraindikace betablokátorů? JACC-CZ 2001; 3: 309-310.
    4. Deedwania, PC, Giles, TD, Klibaner M et al. Efficacy, safety and tolerability of metoprolol CR/ XL in patients with diabetes and chronic heart failure: Experiences from MERIT-HF. Am Heart J 2005; 149: 159-167. Go to original source... Go to PubMed...
    5. ESH-ESC Task Force on the Management of Arterial Hypertension 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension. Journal of Hypertension 2007, 25: 1751-1762. Go to original source... Go to PubMed...
    6. Fonarow, GC. Practical considerations of h-blockade in the management of the post-myocardial infarction patient. Am Heart J 2005; 149: 984-993. Go to original source... Go to PubMed...
    7. Janoušek S. Betablokátory v klinické praxi. Causa subita 2003; 6: 461-465.
    8. Linhart A, Goláň L, Aschermann M. Betablokátory v léčbě arteriální hypertenze. Proč patří mezi léky prvé volby? Kardiol Rev 2001; 3: 186-192.
    9. López-Sendón J, Swedberg K, McMurray J et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004; 25: 1341-1362. Go to original source... Go to PubMed...
    10. Málek F. Betablokátory v terapii ischemické choroby srdeční a chronického srdečního selhání. Interní Med. 2000; 2: 280-283.
    11. Poole-Wilson PA, Swedberg K, Cleland JGF for the COMET investigators: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13. Go to original source... Go to PubMed...
    12. Špinar J, Vítovec a spol. Ischemická choroba srdeční. Grada Praha 2003, s. 361.
    13. The task force on diabetes and cardiovascular disease. Guidelines on diabetes. Pre-diabetes and Cardiovascular Disease: Full text Europ Heart J 2007; 28: 2-72.
    14. Vítovec J, Špinar a kol. Farmakoterapie kardiovaskulárních onemocnění 2. vydání. Grada Praha 2004: s. 248.
    15. Vítovec J, Špinar J. Betablokátory v léčbě chronického srdečního selhání. Jak převést výsledky klinických studií do lékařské praxe. Vnitřní lék. 2000; 46: 161-165.
    16. Task Force Members. Expert consensus dokument on beta-adrenergic receptor blockers. Europ Heart J 2004; 25: 1341-1362. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.